Skip to main content

Randomized clinical trial of intravenous versus intraperitoneal chemotherapy plus bevacizumab in advanced ovarian carcinoma: An NRG oncology/gynecologic oncology group study

Publication ,  Journal Article
Walker, JL; Brady, MF; Wenzel, L; Fleming, GF; Huang, HQ; Disilvestro, PA; Fujiwara, K; Alberts, DS; Zheng, W; Tewari, KS; Cohn, DE; Van Le, L ...
Published in: Obstetrical and Gynecological Survey
August 1, 2019

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Obstetrical and Gynecological Survey

DOI

EISSN

1533-9866

ISSN

0029-7828

Publication Date

August 1, 2019

Volume

74

Issue

8

Start / End Page

474 / 476

Related Subject Headings

  • Obstetrics & Reproductive Medicine
  • 4204 Midwifery
  • 3215 Reproductive medicine
  • 1114 Paediatrics and Reproductive Medicine
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Walker, J. L., Brady, M. F., Wenzel, L., Fleming, G. F., Huang, H. Q., Disilvestro, P. A., … Mannel, R. S. (2019). Randomized clinical trial of intravenous versus intraperitoneal chemotherapy plus bevacizumab in advanced ovarian carcinoma: An NRG oncology/gynecologic oncology group study. Obstetrical and Gynecological Survey, 74(8), 474–476. https://doi.org/10.1097/01.ogx.0000576976.42254.c2
Walker, J. L., M. F. Brady, L. Wenzel, G. F. Fleming, H. Q. Huang, P. A. Disilvestro, K. Fujiwara, et al. “Randomized clinical trial of intravenous versus intraperitoneal chemotherapy plus bevacizumab in advanced ovarian carcinoma: An NRG oncology/gynecologic oncology group study.” Obstetrical and Gynecological Survey 74, no. 8 (August 1, 2019): 474–76. https://doi.org/10.1097/01.ogx.0000576976.42254.c2.
Walker JL, Brady MF, Wenzel L, Fleming GF, Huang HQ, Disilvestro PA, et al. Randomized clinical trial of intravenous versus intraperitoneal chemotherapy plus bevacizumab in advanced ovarian carcinoma: An NRG oncology/gynecologic oncology group study. Obstetrical and Gynecological Survey. 2019 Aug 1;74(8):474–6.
Walker, J. L., et al. “Randomized clinical trial of intravenous versus intraperitoneal chemotherapy plus bevacizumab in advanced ovarian carcinoma: An NRG oncology/gynecologic oncology group study.” Obstetrical and Gynecological Survey, vol. 74, no. 8, Aug. 2019, pp. 474–76. Scopus, doi:10.1097/01.ogx.0000576976.42254.c2.
Walker JL, Brady MF, Wenzel L, Fleming GF, Huang HQ, Disilvestro PA, Fujiwara K, Alberts DS, Zheng W, Tewari KS, Cohn DE, Powell MA, Van Le L, Davidson SA, Gray HJ, Rose PG, Aghajanian C, Myers T, Secord AA, Rubin SC, Mannel RS. Randomized clinical trial of intravenous versus intraperitoneal chemotherapy plus bevacizumab in advanced ovarian carcinoma: An NRG oncology/gynecologic oncology group study. Obstetrical and Gynecological Survey. 2019 Aug 1;74(8):474–476.

Published In

Obstetrical and Gynecological Survey

DOI

EISSN

1533-9866

ISSN

0029-7828

Publication Date

August 1, 2019

Volume

74

Issue

8

Start / End Page

474 / 476

Related Subject Headings

  • Obstetrics & Reproductive Medicine
  • 4204 Midwifery
  • 3215 Reproductive medicine
  • 1114 Paediatrics and Reproductive Medicine